Dr Tri Quoc Du, MD in Dacula, GA - General Practice

Dr Tri Quoc Du, MD is a General Practice physician based in Dacula, Georgia. Dr Tri Quoc Du is licensed to practice in New York (license number 307560) and his current practice location is 1732 Rivercreek Dr, Dacula, Georgia. He can be reached at his office (for appointments etc.) via phone at (281) 636-8899.

NPI number for Dr Tri Quoc Du is 1760441653 and his current mailing address is 1732 Rivercreek Dr, Dacula, Georgia. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1760441653.

Contact Information

	Dr Tri Quoc Du, MD
	1732 Rivercreek Dr, Dacula, GA 30019-7630
	(281) 636-8899
	Not Available

Physician's Profile

Full Name	Dr Tri Quoc Du
Gender	Male
Speciality	General Practice
Location	1732 Rivercreek Dr, Dacula, Georgia
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1760441653
Provider Enumeration Date: 03/21/2006
Last Update Date: 04/15/2021

Medical Identifiers

Medical identifiers for Dr Tri Quoc Du such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1760441653	NPI	-	NPPES
1051039	Medicaid	LA

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208D00000X	General Practice	307560 (New York)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Tri Quoc Du is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Tri Quoc Du, MD 1732 Rivercreek Dr, Dacula, GA 30019-7630 Ph: (281) 636-8899	Dr Tri Quoc Du, MD 1732 Rivercreek Dr, Dacula, GA 30019-7630 Ph: (281) 636-8899

News Archive

Threat from Avian Influenza remains

At the request of the Vietnamese Ministry of Health, World Health Organization (WHO) sent a team of international experts to Viet Nam last week to assess laboratory and epidemiological data on recent cases and determine whether the present level of pandemic alert should be increased.

Electronic Cigarette Association calls for a law restricting the sale of E-Cigarettes to underage smokers

In a letter sent to Congressional members on August 14, the Electronic Cigarette Association (ECA) criticized the recent Food and Drug Administration (FDA) study on electronic cigarettes as it failed to follow standard scientific protocols and was too narrow in scope. In addition, the letter called on Congress to enact legislation that would make it illegal to sell electronic cigarettes to those below the legal age of smoking.

Women are 25% less likely to die post TAVI than men, says doctor

Dr Sherif said: "Earlier studies on the impact of gender on outcome after transcatheter aortic valve implantation (TAVI) have had conflicting results. A Canadian study reported in 641 consecutive patients that female sex is associated with a better long-term and short-term survival after TAVI.1 An Italian study of 305 high risk patients found no gender differences in composite safety and efficacy endpoints at 30 days and one year after TAVI."2

Mouse model may provide clues on mechanism that links diabetes and aging to Alzheimer's

Growing evidence suggests that there may be a link between diabetes and Alzheimer's disease, but the physiological mechanisms by which diabetes impacts brain function and cognition are not fully understood. In a new study published in Aging Cell, researchers at the Salk Institute for Biological Studies show, for the first time, that diabetes enhances the development of aging features that may underlie early pathological events in Alzheimer's.

Shire receives FDA approval for INTUNIV extended release tablets

Shire plc, the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV(TM) (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years.

Dr Tri Quoc Du, MD - General Practice in Dacula, GA